Syncona Portfolio Company Achilles Therapeutics to Pursue Voluntary Liquidation
I'm PortAI, I can summarize articles.
Syncona's board has decided that its portfolio company, Achilles Therapeutics, will pursue a members' solvent voluntary liquidation to return capital to shareholders. Shareholders are expected to receive between 1.20 and 1.32 pounds per share, pending approval at a general meeting on March 20. Syncona holds 11,086,909 American depositary shares in Achilles, valued at 8.5 million pounds as of September 30, 2024.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Trading View The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments